[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369563-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369563-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","targeting-theshoc2ras-interaction-in-ras-mutant-cancers-research-article","Targeting theSHOC2–RAS interaction in RAS-mutant cancers - Research article","","Activating mutations in HRAS, NRAS, and KRAS drive frequent oncogenic signalling in human cancers, yet therapies are unevenly developed, with a major gap for NRAS(Q61*) mutants. The study identifies SHOC2, a component of the SHOC2–MRAS–PP1C complex, as a nucleotide-state-dependent and isoform-agnostic dependency of RAS(Q61*) tumours. An oncogenic NRAS(Q61R) direct interaction with SHOC2 is demonstrated by X-ray co-crystal structure, enabling small-molecule disruption and a tool compound that inhibits MAPK signalling and proliferation in RAS-mutant models.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/targeting-theshoc2ras-interaction-in-ras-mutant-cancers-research-article/369563/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/targeting-theshoc2ras-interaction-in-ras-mutant-cancers-research-article/369563.png","ImageObject",300,407,{"name":42,"@type":43},"Angel","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-08","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What does the study identify as a dependency in RAS(Q61*) tumours?","Question",{"text":63,"@type":64},"SHOC2 is identified as a dependency of RAS(Q61*) tumours in a nucleotide-state-dependent and isoform-agnostic manner.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How is the SHOC2 interaction with oncogenic NRAS supported?",{"text":68,"@type":64},"Mechanistic experiments show that oncogenic NRAS(Q61R) forms a direct interaction with SHOC2, supported by an X-ray co-crystal structure.",{"name":70,"@type":61,"acceptedAnswer":71},"What was achieved by targeting SHOC2 with small molecules?",{"text":72,"@type":64},"Small molecules discovered through screening bind to SHOC2 and disrupt the NRAS(Q61*) interaction, leading to a cellularly active tool compound that inhibits MAPK signalling and proliferation in RAS-mutant cancer models.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369563,1790249264,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},687207412472,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Targeting theSHOC2–RAS interaction in RAS-mutant cancers  \n\n| [https://doi.org/10.1038/s41586-025-08931-1](https://doi.org/10.1038/s41586-025-08931-1)\u003Cbr>Received: 8 May 2024 Accepted: 24 March 2025 Published online: 7 May 2025 Open access\u003Cbr> Check for updates | Zachary J. Hauseman1,3, Frédéric Stauffer2,3, Kim S. Beyer2,3, Sandra Mollé2,\u003Cbr>Elena Cavicchioli2, Jean-Remy Marchand2, Michelle Fodor1, Jessica Viscomi1,\u003Cbr>Anxhela Dhembi1, Stéphanie Katz2, Beatrice Faggion2, Mylene Lanter2, Grainne Kerr2, DanielaSchildknecht2, Cornelia Handl2, Danilo Maddalo2, Carole Pissot Soldermann2, Jacob Brady1, Om Shrestha1, Zachary Nguyen1, Lukas Leder2, Gregor Cremosnik2, Sandra Lopez Romero2, Ulrich Hassiepen2, Travis Stams1, Markus Linder2, Giorgio G. Galli2, DanielA. Guthy2, DanielA. King1, Sauveur-Michel Maira2, Claudio R. Thoma1,\u003Cbr>Veronika Ehmke2 ✉ & Luca Tordella2 ✉\u003Cbr>Activating mutationsintherat sarcoma (RAS) genes HRAS, NRASand KRAS collectively represent the most frequent oncogenicdriver inhuman cancer1. They have previously been considered undruggable, but advances in the past few years have ledtothe clinical development of agents that target KRAS(G12C) and KRAS(G12D) mutants, yielding promises of therapeutic responsesat tolerated doses2. However, clinical agents that selectively target NRAS(Q61*) mutants (* represents ‘any’), the secondmost-frequent oncogenicdriver in melanoma, are still lacking. Here we identify SHOC2, a component of theSHOC2–MRAS–PP1C complex, asa dependency of RAS(Q61*) tumours ina nucleotide-state-dependent and isoform-agnostic manner. Mechanistically, we found that oncogenicNRAS(Q61R) forms a direct interaction with SHOC2, evidenced by X-ray co-crystal structure. In vitro high-throughput screening enabled the discovery of small molecules that bind toSHOC2 and disrupt the interaction with NRAS(Q61*). Structure-based optimization led toa cellularly active tool compound that shows inhibition of mitogen-activated protein kinase (MAPK) signalling and proliferation in RAS-mutant cancer models, most notably inNRAS(Q61*) settings. These findings provide evidence fora neomorphSHOC2–(canonical)RAS protein interaction that ispharmacologically actionable and relevant to cancer sustenance. Overall, this work provides the concept validation and foundation for developing new therapies atthe core oftheRAS signalling pathway. |  |\n| --- | --- | --- |\n| The canonical RAS protein family consists of three members: HRAS, |  | approved for this patient population, currently representing a large |\n| NRASand KRAS. Their activity is regulated by binding to guanosine |  | unmet medical need5. All RAS oncogenic mutations promote a shift |\n| diphosphate (GDP) or guanosine triphosphate (GTP), corresponding |  | towards a higher prevalence oftheRAS active state by disrupting GTP |\n| to structural changes in the switch regions and resulting in inactive or |  | hydrolysis, but the extent varies, depending on the specific mutation. |\n| active states, respectively. In the GTP-bound active state, RAS proteins |  | These differences can be explained by different biochemical properties |\n| form productive interactions with effector proteins, most importantly |  | (differences in intrinsic hydrolysis rates or nucleotide exchange rates) |\n| RAF family members, leading to downstream activation of theMAPK |  | and conformations that favour effector binding to various degrees and |\n| signalling pathway3. TheRAS–RAF–MAPK axis controls cell prolifera- |  | that overall may result ina differential interactome and/or strength of |\n| tion and is constitutively activated by mutations at different levels of |  | downstream signalling6. Targeting specific RAS-mutant addictions or |\n| the pathway in most human cancers. Mutations of RAS proteins take |  | co-dependencies may represent an alternative to the development of |\n| place with relatively high frequency at positions 12, 13 and 61, with |  | agents that directly engage mutated RAS, although so far","cbCaijGNcLx98LuY","https://ap.wps.com/l/cbCaijGNcLx98LuY","pdf",10373190,35,"English","# Background and clinical need\n## RAS oncogenic signaling and NRAS(Q61*) gap\n# Discovery of SHOC2 dependency\n## Nucleotide-state and isoform-agnostic requirement\n# Mechanistic interaction and structural evidence\n## NRAS(Q61R)–SHOC2 direct binding\n# Small-molecule targeting strategy\n## High-throughput screening and optimization\n# Functional outcomes in cancer models\n## MAPK inhibition and proliferation suppression","[{\"question\":\"What does the study identify as a dependency in RAS(Q61*) tumours?\",\"answer\":\"SHOC2 is identified as a dependency of RAS(Q61*) tumours in a nucleotide-state-dependent and isoform-agnostic manner.\"},{\"question\":\"How is the SHOC2 interaction with oncogenic NRAS supported?\",\"answer\":\"Mechanistic experiments show that oncogenic NRAS(Q61R) forms a direct interaction with SHOC2, supported by an X-ray co-crystal structure.\"},{\"question\":\"What was achieved by targeting SHOC2 with small molecules?\",\"answer\":\"Small molecules discovered through screening bind to SHOC2 and disrupt the NRAS(Q61*) interaction, leading to a cellularly active tool compound that inhibits MAPK signalling and proliferation in RAS-mutant cancer models.\"}]","Targeting theSHOC2–RAS interaction in RAS-mutant cancers - Research article | PDF",1790183439,88,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6e99bb9c456f1c31c56c367d5ef9e2c7.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6386a7797004222318ec322d222795c6.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/31f368ba79022a3b3695bf2b554b5790.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/652c33afb571333f77ecbb7f7bf80d69.webp",980,1301]